[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 4774 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  2d Session
                                S. 4774

To provide for the periodic issuance of up-to-date clinical guidance on 
 addressing the health effects of per- and polyfluoroalkyl substances 
                    (PFAS), and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 25, 2024

  Mrs. Shaheen (for herself and Ms. Collins) introduced the following 
  bill; which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
To provide for the periodic issuance of up-to-date clinical guidance on 
 addressing the health effects of per- and polyfluoroalkyl substances 
                    (PFAS), and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Better Care for PFAS Patients Act of 
2024''.

SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, RECOMMENDATIONS, AND GUIDANCE.

    (a) Periodic Assessment and Recommendations.--
            (1) Agreement.--The Director of the Agency for Toxic 
        Substances and Disease Registry (in this section referred to as 
        the ``Director'') shall enter into an agreement with the 
        National Academies of Sciences, Engineering, and Medicine (or 
        another appropriate entity if the National Academies declines 
        to enter into such agreement) under which the National 
        Academies or the other appropriate entity agrees--
                    (A) to assess the health effects of per- and 
                polyfluoroalkyl substances (in this section referred to 
                as ``PFAS'') that can be measured in human tissues;
                    (B) to formulate clinical recommendations on 
                addressing such health effects;
                    (C) not later than 2 years after the date of entry 
                into such agreement, to complete the initial assessment 
                under subparagraph (A) and formulate the initial 
                recommendations under subparagraph (B); and
                    (D) to update the most recent assessment and 
                recommendations under this paragraph--
                            (i) every 5 years; or
                            (ii) more frequently as determined 
                        necessary by the Director based on an 
                        assessment of the science.
            (2) Consultation.--In carrying out the assessments under 
        paragraph (1), the National Academies of Sciences, Engineering, 
        and Medicine or other appropriate entity shall engage with PFAS 
        exposed communities and solicit input from members of such 
        communities regarding their experiences with PFAS exposure, 
        testing, and clinical follow-up.
            (3) Timing of entry into agreement.--The Director shall 
        enter into the agreement required by paragraph (1) not later 
        than 60 days after the date of enactment of this Act.
    (b) Up-to-Date Guidance.--Based on the results of the most recent 
assessment and recommendations under subsection (a), the Director, in 
consultation with the entity with which the Director enters into the 
agreement under subsection (a), shall--
            (1) not later than 5 years after the date of entry into the 
        agreement required by subsection (a)--
                    (A) issue up-to-date clinical guidance on 
                addressing the health effects of PFAS;
                    (B) post such guidance on the public website of the 
                Agency for Toxic Substances and Disease Registry; and
                    (C) disseminate such guidance to State and local 
                public health authorities and appropriate health care 
                professionals; and
            (2) every 5 years thereafter, or more frequently as 
        determined necessary by the Director based on an assessment of 
        the science, issue, post, and disseminate up-to-date guidance 
        as described in paragraph (1).
                                 <all>